OPKO Health (OPK) Competitors $1.23 +0.04 (+2.94%) As of 12:10 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OPK vs. LGND, FOLD, BCRX, CLDX, DVAX, MNKD, NVAX, INVA, GERN, and ZBIOShould you be buying OPKO Health stock or one of its competitors? The main competitors of OPKO Health include Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), MannKind (MNKD), Novavax (NVAX), Innoviva (INVA), Geron (GERN), and Zenas BioPharma (ZBIO). These companies are all part of the "biotechnology" industry. OPKO Health vs. Its Competitors Ligand Pharmaceuticals Amicus Therapeutics BioCryst Pharmaceuticals Celldex Therapeutics Dynavax Technologies MannKind Novavax Innoviva Geron Zenas BioPharma OPKO Health (NASDAQ:OPK) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability. Which has preferable earnings and valuation, OPK or LGND? Ligand Pharmaceuticals has lower revenue, but higher earnings than OPKO Health. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOPKO Health$713.10M1.36-$53.22M-$0.25-4.90Ligand Pharmaceuticals$167.13M15.44-$4.03M-$7.12-18.79 Does the media refer more to OPK or LGND? In the previous week, OPKO Health had 4 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 12 mentions for OPKO Health and 8 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.32 beat OPKO Health's score of -0.32 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OPKO Health 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral Ligand Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals hold more shares of OPK or LGND? 64.6% of OPKO Health shares are held by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 49.7% of OPKO Health shares are held by insiders. Comparatively, 7.0% of Ligand Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility & risk, OPK or LGND? OPKO Health has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Is OPK or LGND more profitable? OPKO Health has a net margin of -26.68% compared to Ligand Pharmaceuticals' net margin of -73.07%. Ligand Pharmaceuticals' return on equity of -7.83% beat OPKO Health's return on equity.Company Net Margins Return on Equity Return on Assets OPKO Health-26.68% -13.17% -8.28% Ligand Pharmaceuticals -73.07%-7.83%-6.92% Do analysts recommend OPK or LGND? OPKO Health presently has a consensus target price of $2.75, suggesting a potential upside of 124.49%. Ligand Pharmaceuticals has a consensus target price of $150.00, suggesting a potential upside of 12.12%. Given OPKO Health's higher probable upside, equities research analysts clearly believe OPKO Health is more favorable than Ligand Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OPKO Health 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00Ligand Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryOPKO Health beats Ligand Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get OPKO Health News Delivered to You Automatically Sign up to receive the latest news and ratings for OPK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OPK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OPK vs. The Competition Export to ExcelMetricOPKO HealthMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$971.49M$6.80B$5.56B$9.46BDividend YieldN/A1.31%4.74%4.13%P/E Ratio-4.9021.7129.0024.16Price / Sales1.3677.45430.46176.66Price / Cash17.3020.8324.4827.20Price / Book0.614.728.515.73Net Income-$53.22M$176.39M$3.25B$265.17M7 Day Performance-9.26%-3.58%-1.51%-2.63%1 Month Performance-8.92%-3.01%7.17%6.35%1 Year Performance-9.26%11.44%26.35%19.94% OPKO Health Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OPKOPKO Health4.1072 of 5 stars$1.23+2.9%$2.75+124.5%-11.9%$971.49M$713.10M-4.902,997Earnings ReportLGNDLigand Pharmaceuticals4.1832 of 5 stars$134.92-0.7%$147.17+9.1%+32.5%$2.60B$167.13M-18.9580Positive NewsUpcoming EarningsFOLDAmicus Therapeutics4.001 of 5 stars$6.12+1.0%$16.22+165.1%-37.3%$1.88B$528.29M-67.99480News CoverageAnalyst UpgradeBCRXBioCryst Pharmaceuticals4.3925 of 5 stars$8.26-3.4%$16.70+102.2%+13.2%$1.73B$503.49M-31.77530News CoverageEarnings ReportGap UpCLDXCelldex Therapeutics1.2642 of 5 stars$22.01-5.7%$50.11+127.7%-36.2%$1.46B$7.02M-8.15150News CoverageUpcoming EarningsDVAXDynavax Technologies4.2002 of 5 stars$11.29-0.6%$24.00+112.6%+3.1%$1.36B$277.25M-21.71350Positive NewsUpcoming EarningsMNKDMannKind3.4146 of 5 stars$3.96-2.5%$9.86+148.9%-29.8%$1.20B$297.60M39.60400Upcoming EarningsAnalyst DowngradeNVAXNovavax4.5823 of 5 stars$7.28-2.5%$15.86+117.8%-44.3%$1.18B$682.16M2.751,990Upcoming EarningsINVAInnoviva4.2626 of 5 stars$18.54-1.0%$40.33+117.5%-2.4%$1.16B$358.71M-18.36100News CoverageGERNGeron3.0375 of 5 stars$1.15-8.7%$4.61+301.0%-74.4%$732.46M$76.99M-5.48229Upcoming EarningsZBIOZenas BioPharma1.7574 of 5 stars$16.45+5.0%$36.67+122.9%N/A$688.17M$15M-4.63N/APositive News Related Companies and Tools Related Companies LGND Competitors FOLD Competitors BCRX Competitors CLDX Competitors DVAX Competitors MNKD Competitors NVAX Competitors INVA Competitors GERN Competitors ZBIO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OPK) was last updated on 8/4/2025 by MarketBeat.com Staff From Our PartnersThe Altcoin That Could be Poised to Benefit Most from Trump’s ReturnWith Trump back in office, the crypto tide is turning fast. Regulation is easing. Momentum is building. And ac...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OPKO Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OPKO Health With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
